Form 6K Artrya Ltd For: 16 June
- Investing.com
Metrics to compare | AYA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAYAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −25.5x | −2.6x | −0.4x | |
PEG Ratio | −5.69 | 0.00 | 0.00 | |
Price/Book | 8.2x | 4.5x | 2.6x | |
Price / LTM Sales | 22,931.3x | 4.4x | 3.0x | |
Upside (Analyst Target) | 52.0% | 61.1% | 54.5% | |
Fair Value Upside | Unlock | −1.0% | 7.2% | Unlock |
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. It offers Salix, a suite of cloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. The company was incorporated in 2018 and is based in West Perth, Australia.